drugset
drugset / Trial / NCT03475407

The Effects of Intravitreal Ozurdex Implant in DME

NCT03475407 ↗

Phase 4 Unknown 20 enrolled Nune Eye Hospital, Seoul, Korea
NaSingle-groupOpen-labelTreatment

Summary

Intravitreal Ozurdex implant therapy improves visual outcome and OCT findings. The purpose of this study is that these results are correlated with the change of cytokine level known to be increased in DME patients.

Timeline

Start
2015-03
Primary completion
2018-06
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule — Intravitreal

Indications

diabetic macular edema